Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that azelaic acid entrapped in transethosomes exhibited enhanced antidermatophyte activity and improved treatment outcomes in guinea pig models of dermatophytosis compared to free azelaic acid.

This review discusses azelaic acid's mechanisms and uses in dermatology, noting its effectiveness in treating conditions like rosacea, acne, and melasma, but reports no new clinical results.

This systematic review explored the potential of cetirizine, an anti-inflammatory antihistamine, as a complementary treatment for androgenetic alopecia, reporting that it might help prevent hair follicle miniaturization by reducing inflammation and modulating immune activity, without notable side effects.

In this retrospective pharmacovigilance study, researchers analyzed over 7,900 adverse event reports related to aromatase inhibitors, identifying common side effects and toxicological mechanisms to highlight potential safety concerns in treating postmenopausal hormone receptor-positive breast cancer.

This study highlights that azelaic acid, initially recognized for skin hypopigmentation, shows potential in treating various skin conditions due to its complex mechanisms, even though these are not yet fully understood, indicating a need for further research.

This article reviews the use of bimatoprost for eyelash hypotrichosis and reports its effectiveness in promoting eyelash growth but highlights uncertain efficacy in cases of eyelash alopecia areata.

This study reported that after 7.5 months of treatment, topical Alfatradiol significantly increased anagen hair rates in women and men with androgenetic alopecia, with minimal side effects.

This reference compilation details potential adverse skin reactions and other side effects associated with the antihypertensive drug Quinazil, including rare cases of skin angioedema and other dermatological reactions.

This case collection reports that 15% azelaic acid gel can be effectively used as a monotherapy to treat mild-to-moderate adult female acne.

In this study, researchers found that microinfusion of dutasteride using the MMP® technique did not show a statistical difference compared to placebo in clinical assessments for male androgenetic alopecia, though patients reported improvements in the vertex area.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

This study evaluated current treatments for pediatric alopecia areata and found that high potency topical steroids had the strongest supporting evidence, with promising results also observed for anthralin ointment and other treatments in lower-grade studies.

This article presents two cases of anagen effluvium following oral albendazole use and summarizes previously reported cases, suggesting this side effect may occur with this drug.

This study developed a consensus document to guide danazol discontinuation in hereditary angioedema patients, enhancing the standardization and safety of treatment protocols.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

This letter to the editor discusses the use of topical cetirizine 1% for treating androgenetic alopecia but reports no new clinical outcomes.

In this case report, azathioprine was linked to anagen effluvium in a 36-year-old woman after two weeks of use; hair regrowth occurred once the drug was stopped and minoxidil treatment was started.

The trial helped find the best dose of deuruxolitinib for treating alopecia areata.

This study found that azathioprine pulse therapy and betamethasone both effectively managed alopecia areata with similar hair regrowth results, though betamethasone had significantly more side effects, suggesting azathioprine as a preferable alternative to corticosteroids.

This study found that unilateral topical latanoprost use for glaucoma was associated with hypertrichosis and increased pigmentation of eyelashes in the treated eye compared to the untreated eye.

In this study, Astragaloside IV was found to inhibit apoptosis-related pathways in hair follicles of mice, suggesting it may serve as an alternative therapy for hair loss.

This study suggests that HDAC inhibitors, such as Vorinostat and Entinostat, could be effective in promoting hair regrowth in a mouse model of alopecia areata.

This study found that 4-MA is a potent inhibitor of testosterone 5α-reductase in human tissues, promising potential for treating androgen-dependent skin conditions like male pattern baldness.

This case report describes two patients who experienced loose anagen hairs and pili torti, resulting in nonscarring alopecia, potentially linked to erlotinib treatment for solid tumors.

This study reports the first case of eyelash elongation and thickening in a patient with hypereosinophilic syndrome taking the Janus kinase inhibitor ruxolitinib.

In this study, both topical minoxidil and latanoprost were found to improve dermoscopic features of alopecia areata, with latanoprost showing superior effectiveness; minor side effects included erythema and itching.

This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.

This study found that alopecia areata patients with eosinophilia were more likely to have severe hair loss, atopia, and nail abnormalities compared to those without eosinophilia.

In this case report, a severe case of pediatric alopecia areata was treated with topical ruxolitinib, a Janus kinase inhibitor, highlighting the limited but promising evidence for this treatment in children.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.